Hepatitis News and Research

RSS

Human antibodies that thwart the SARS virus in mice can be mass-produced quickly

Human antibodies that thwart the SARS virus in mice can be mass-produced quickly using a new laboratory technique developed by an international research team collaborating with the National Institute of Allergy and Infectious Diseases (NIAID).

12 Jul 2004

Myriad Genetics awarded a $14.2 million contract for AIDS and hepatitis research

Myriad Genetics has announced that it has been awarded a five-year, $14.2 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

10 Jul 2004

McGuinty government commits to hepatitis C federal funding

The McGuinty government is committed to spending all of the federal funding for Ontarians infected with hepatitis C through the blood system prior to 1986 and after 1990, Health and Long-Term Care Minister George Smitherman announced today.

10 Jul 2004

Researchers found that a significant number of men get the hepatitis B virus behind bars

In the first study to gauge the risks of contracting HIV and hepatitis in Rhode Island prisons, Brown University researchers found that a significant number of men get the hepatitis B virus behind bars – a finding that led the team to call for prison-wide vaccinations. Results are published in the current edition of the American Journal of Public Health.

7 Jul 2004

Treatment of chronic hepatitis C with interferon can be ineffective due to relapse

Treatment of chronic hepatitis C with interferon can be ineffective due to relapse. We aimed to reduce the 40% relapse rate of 6 months interferon–ribavirin combination therapy by prolonging treatment to 18 months.

4 Jul 2004

New research may help doctors diagnose diseases like HIV and hepatitis C earlier

A new method developed by researchers at the National Institute of Standards and Technology for accurately measuring the concentration of artificial viruses in a solution may ultimately help doctors diagnose diseases like HIV and hepatitis C earlier.

2 Jul 2004

The EU is contributing €9 million to the “Vigilance against Viral Resistance” (VIRGIL) project

Viruses’ growing resistance to drugs means diseases such as hepatitis B and C are increasingly difficult to treat. New pandemics may arise with unforeseeable consequences.

29 Jun 2004

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people or 10% of the 500,000 people in the U.S with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery for coverage of life saving drugs.

26 Jun 2004

SARS, the highly infectious respiratory virus, has been found in tears

The finding suggests that tear analysis could not only be an effective means of diagnosing the infection, but also an unrecognised source of its spread, if appropriate preventive measures are not taken, say the authors.

20 Jun 2004

Harmless virus known as GBV-C slows the progression of HIV

Iowa City Veterans Affairs (VA) Medical Center and University of Iowa (UI) researchers have unlocked part of the mystery of how a harmless virus known as GBV-C slows the progression of HIV and prolongs survival for many patients.

17 Jun 2004

Australian researchers awarded funding for new HIV vaccines

Australian researchers at Monash University have been awarded $488,125 in development grants by the National Health and Medical Research Council (NHMRC) for projects exploring new vaccines for HIV, the development of medical diagnostic devices and the development of drugs to treat metastatic cancers.

17 Jun 2004

Call for special help for young people who inject drugs

Government and health care services are being urged to make special help available for young people who inject drugs, in a bid to minimize drug-related deaths.

16 Jun 2004

World Blood Donor Day

The world today honours voluntary blood donors for their priceless contribution to their communities. However, while celebrations take place in many cities around the world, numerous patients and trauma victims in those same cities will be dying or suffering unnecessarily because of a shortage of blood.

11 Jun 2004

UK's Hepatitis C ex-gratia payment scheme to launch

The Skipton Fund, the body set up to administer the UK-wide ex gratia payment scheme for people infected with Hepatitis C from NHS blood or blood products, will launch and begin processing applications on July 5 2004.

3 Jun 2004

Breakthrough in gene therapy

Despite a roller-coaster ride of ups and downs during the past 15 years, gene therapy has continued to attract many of the world's brightest scientists. They are tantalized by the enormous potential that replacing missing genes or disabling defective ones offers for curing diseases of many kinds.

3 Jun 2004

Tuberculosis test kits order

Medical Services International Inc.has announced that it has received its first order for the VScan Tuberculosis (TB) rapid test kit from a prominent pharmaceutical company that produces Tuberculosis vaccines.

2 Jun 2004

Myth of disease threat posed by dead bodies after natural disasters unfounded

Fears that dead bodies will spread infection and disease following natural disasters are largely baseless, and simply serve to prolong the suffering of surviving friends and family members, according a scientific article published today.

1 Jun 2004

Marijuana use does not appear to be associated with an increased risk of developing oral cancer

Contrary to previous research findings that have suggested a link, marijuana use does not appear to be associated with an increased risk of developing oral cancer, according to a large, population-based study led by researchers at Fred Hutchinson Cancer Research Center.

1 Jun 2004

Treatment helps 26% of black Americans with chronic hepatitis C

Twenty-six percent (26%) of black Americans (BA) with chronic hepatitis C who received treatment with Pegasys plus Copegus (peginterferon alfa-2a plus ribavirin) achieved a sustained virological response (SVR), according to study results published in the June 2004 issue of Hepatology.

1 Jun 2004

Blueprint for rational design of vaccines that induce desired T-cell responses

Investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have conducted studies in mice to gain a new picture of how the immune system’s “killer” T cells are prompted to destroy infected cells. Their insights provide a blueprint for rational design of vaccines that induce desired T-cell responses.

27 May 2004

Hepatitis News and Research

Human antibodies that thwart the SARS virus in mice can be mass-produced quickly

Myriad Genetics awarded a $14.2 million contract for AIDS and hepatitis research

McGuinty government commits to hepatitis C federal funding

Researchers found that a significant number of men get the hepatitis B virus behind bars

Treatment of chronic hepatitis C with interferon can be ineffective due to relapse

New research may help doctors diagnose diseases like HIV and hepatitis C earlier

The EU is contributing €9 million to the “Vigilance against Viral Resistance” (VIRGIL) project

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

SARS, the highly infectious respiratory virus, has been found in tears

Harmless virus known as GBV-C slows the progression of HIV

Australian researchers awarded funding for new HIV vaccines

Call for special help for young people who inject drugs

World Blood Donor Day

UK's Hepatitis C ex-gratia payment scheme to launch

Breakthrough in gene therapy

Tuberculosis test kits order

Myth of disease threat posed by dead bodies after natural disasters unfounded

Marijuana use does not appear to be associated with an increased risk of developing oral cancer

Treatment helps 26% of black Americans with chronic hepatitis C

Blueprint for rational design of vaccines that induce desired T-cell responses

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News